Brit J Heamatol: LDL receptorison is a negative prognosis factor in patients with acute myeloid leukemia
-
Last Update: 2020-07-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The LDL receptor (LDLR) is a membrane receptor that mediates the cytoswallowing effect of LDLIt has been suggested that the absorption of LDL promotes in vitro resistance to chemotherapy for acute myeloid leukemia (AML) cell lines, researchers analyzed LDLR expression and patient survival rates using bone marrow biopsy samples from 187 patients receiving AML intensive treatment, in a study published in the journal British Journal of Blood System Diseasesthe study found that the increase in LDLR expression was related to the overall patient (58.4%, 44.2% and 24.4% ;P 0.0018) and the decrease in event-free survival rates (41.7%, 18.1% and 14.3% ;P .0077), as well as the increasein cumulative recurrence rate (33.9%, 55.1% and 71.4% ;P.0111)In two internationally validated queues, 557 patients who underwent intensive treatment confirmed the correlation between LDLR expression and survivalIn the analysis and validation queue, multivariate regression analysis(including the European LeukemiaNet genetic risk classification) showed that LDLR expression was still associated with patient outcomesldLR can therefore predict apatient outcome for AMLIn addition, the researchers found that LDLR had lower levels of expression in most healthy tissues, suggesting that it was a more promising target for antibody-based treatment in AML patients
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
